Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1669201

	registered interest
	date	10/11/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Innovative Medicines Fund: Gene Therapies
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the Innovative Medicines Fund in increasing access to gene therapies.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	1326
	answer	answer is ministerial correction date of answer 16/11/2023 answer text <p>The National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service in England on whether all new licensed medicines represent a clinically effective and cost-effective use of NHS resources. NICE has been able to recommend several gene therapies for routine funding and they are now routinely available to NHS patients in line with NICE’s recommendations. No gene therapies have been recommended for use through the Innovative Medicines Fund and NICE continues to consider the suitability of medicines for the Fund with individual companies.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/11/2023 17:26:10 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3960 label Biography information for Henry Smith

1670746

	registered interest
	date	17/11/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential implications for his policies of (a) updates to the programme manual used by the National Institute of Health and Care Excellence including Rapid Access to Managed Access and (b) the introduction of the Innovative Medicines Fund.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	2397
	answer	answer is ministerial correction date of answer 22/11/2023 answer text <p>The Government is committed to supporting rapid patient access to effective new medicines in a way that is fair to all parties and represents value to the National Health Service. The National Institute for Health and Care Excellence (NICE) plays an important role in supporting patient access to effective new medicines and is able to recommend most new medicines for use in the NHS. Where there is too much clinical uncertainty for NICE to be able to recommend routine funding, it is able to recommend medicines for use through the Cancer Drugs Fund or Innovative Medicines Fund which make promising medicines available to patients while further real-world evidence is collected to inform a final NICE recommendation.</p><p>NICE is responsible for the methods and processes it uses in the evaluation of new medicines and the changes that it has recently made to its evaluation processes will enable it to produce faster guidance on simpler, low-risk treatments. NICE and NHS England are exploring options for rapid entry to managed access (REMA) that build on the experience of the Cancer Drugs Fund and Innovative Medicines Fund to support managed access to medicines. NICE has not yet made any changes to its health technology evaluation manual related to REMA.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/11/2023 15:53:14 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3960 label Biography information for Henry Smith

1671983

	registered interest
	date	21/11/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Bowel Cancer: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to help increase access to bowel cancer screenings.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	2858
	answer	answer is ministerial correction date of answer 27/11/2023 answer text <p>Based on advice from the UK National Screening Committee, the National Health Service is currently extending the age criteria for bowel cancer screening from between 60 and 74 years old so that screening will be available from the age of 50 years old; this is due to be completed by 2024/25. This will increase access for people who would have otherwise not been able to access the service.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 27/11/2023 16:11:07 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3960 label Biography information for Henry Smith

1678211

	registered interest
	date	14/12/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health Services: Trade Competitiveness
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether she is taking steps to protect (a) Bupa, (b) HCA Healthcare and (c) other major private healthcare providers from (i) BGI Group and (ii) MGI Tech.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	7019
	answer	answer is ministerial correction date of answer 19/12/2023 answer text <p>Organisations which hold sensitive biological data are subject to the UK General Data Protection Regulation (GDPR). In addition, organisations such as Genomics England, UK Biobank and NIHR BioResource actively consider national security in decision making about partnerships with companies overseas.</p><p>As part of the new UK Biological Security Strategy, the Government is undertaking a programme of work to assess how we can minimise the risks from biological data to protect our burgeoning bioeconomy, without stifling innovation, and build confidence in sharing personal data to improve health outcomes in the United Kingdom and across the world. The Office for Life Sciences has begun this work, in consultation with relevant Departments and Agencies across Government, and key partners such as Genomics England and UK Biobank.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 19/12/2023 16:02:28 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3960 label Biography information for Henry Smith

1678334

	registered interest
	date	15/12/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	DNA: Databases
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure the security of DNA data held by (a) the NHS Genomic Medicine Service and (b) private providers of NHS healthcare; and whether she has had discussions with Cabinet colleagues on the potential for cyber attacks by foreign state-linked companies.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	7190
	answer	answer is ministerial correction date of answer 19/12/2023 answer text <p>Organisations which hold sensitive biological data are subject to the UK General Data Protection Regulation. In addition, organisations such as Genomics England, UK Biobank and NIHR BioResource actively consider national security in decision making about partnerships with companies overseas.</p><p>As part of the new UK Biological Security Strategy, the Government is undertaking a programme of work to assess how we can minimise the risks from biological data to protect our burgeoning bioeconomy, without stifling innovation, and build confidence in sharing personal data to improve health outcomes in the United Kingdom and across the world. The Office for Life Sciences has begun this work, in consultation with relevant Departments and Agencies across Government, and key partners such as Genomics England and UK Biobank.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 19/12/2023 16:10:23 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3960 label Biography information for Henry Smith

1685250

	registered interest
	date	26/01/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS and Social Services: Veganism and Vegetarianism
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure that vegans and vegetarians are provided with appropriate food in the (a) NHS, (b) social care and (c) other health services.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	11599
	answer	answer is ministerial correction date of answer 05/02/2024 answer text <p>For the National Health Service, social care and other health services, the Care Quality Commission regulates providers on compliance with Regulation 14 of the Health and Social Care Act 2008 (Regulated Activities) Regulations 2014. This states that health and social care providers must consider people’s preferences, religious and cultural backgrounds when providing food and drink, and that people must have their nutritional needs assessed as quickly as possible and food be provided to meet the needs identified.</p><p>NHS England published updated NHS Food Standards in November 2022. The standards set out that menus should be tailored to meet patient’s dietary requirements and personal preferences. To that end, all hospital sites are expected to prepare and provide menus that meet all necessary types of dietary, religious and cultural needs. Vegetarian and vegan meals and snacks have long been part of this choice, and particularly with the focus on providing lower carbon choices, plant based meals are being provided as an extensive range.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 05/02/2024 13:00:34 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3960 label Biography information for Henry Smith

1691572

	registered interest
	date	26/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cardiovascular Diseases: Research
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help encourage research into cardiovascular disease (a) treatment and (b) prevention.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	15618
	answer	answer is ministerial correction date of answer 04/03/2024 answer text <p>The Department funds research into the treatment and prevention of cardiovascular disease through the National Institute for Health and Care Research (NIHR). In January 2023, the Department updated its areas of research interest (ARIs), which highlight to the patient, academic, clinical and life sciences community the areas where we want to expand our efforts and work together to systematically understand, intervene and improve public, patient, and service outcomes. ARI1 focuses on prevention, early diagnosis and appropriate intervention for people at increased risk of poor health, including cardiovascular disease. Supporting ARI1, the three NIHR Research Schools were awarded £10 million to deliver a collaborative programme of prevention research between 2023 and 2027. The programme will have a strong emphasis on capacity building. It will also encourage practitioners to participate in prevention research as a step towards establishing their own longer-term research careers and help address gaps between research and practice.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 04/03/2024 15:42:10 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3960 label Biography information for Henry Smith

1700141

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Bowel Cancer: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help improve genomics testing for bowel cancer patients.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	20972
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>A National Health Service testing programme is helping to diagnose thousands of people with a genetic condition, Lynch Syndrome, that increases the chance of developing certain cancers including bowel cancer. The national programme ensures all people diagnosed with bowel cancer are offered genomic testing, with a diagnosis for Lynch Syndrome not only helping to guide more personalised cancer treatment but enabling their families and relatives to be offered testing too. Relatives who receive a diagnosis of Lynch Syndrome can be referred to genetic services to discuss regular testing options to help catch any cancers as early as possible, as well as to consider preventive options such as taking aspirin or undergoing risk-reducing surgery.</p><p>Genomic testing in the NHS in England is provided through the NHS Genomic Medicine Service (GMS) and delivered by a national genomic testing network of seven NHS Genomic Laboratory Hubs (GLHs). The NHS GLHs deliver testing as directed by the National Genomic Test Directory (NGTD) which outlines the full range of genomic testing offered by the NHS in England including tests for 3,200 rare diseases and over 200 cancer clinical indications, including both whole genome sequencing (WGS) and non-WGS testing. The NGTD sets out the eligibility criteria for patients to access testing as well as the genomic targets to be tested and the method that should be used, including testing for bowel cancer patients.</p><p>The NHS GMS cancer genomic testing strategy has facilitated a move to a consolidated laboratory network through the seven NHS GLHs delivering more extensive panel testing using cutting edge high throughput Next Generation Sequencing (NGS) technology. For patients, including those with bowel cancer, this technology enables testing for a larger number of genetic variations to give a more precise diagnosis, identify biomarkers to target treatment and opportunities to access innovative medicines, and can support enrolment into molecularly stratified clinical trials.</p><p>Testing is available for all eligible patients across the whole of England. Individuals should discuss with their healthcare professional (for example, their general practitioner or other healthcare professional if they are already being seen in a relevant service) whether genomic testing is appropriate for them. Their healthcare professional will then make a decision whether to refer the individual either directly or via an NHS clinical genomics service or other relevant clinical speciality for genomic testing following clinical review of their and their family’s medical history if known, and the relevant genomic testing eligibility criteria.</p><p>The 17 NHS Clinical Genomic Services (NHS CGSs), commissioned by NHS England, deliver a comprehensive clinical genomic and counselling service that directs the diagnosis, risk assessment and lifelong clinical management of patients of all ages and their families who have, or are at risk of having, a rare genetic or genomic condition. As part of the NHS CGS, the patient and their family will access diagnosis, and management relevant to their particular condition, but also receive support and guidance so that they are able to understand their condition, its implications, and their options in relation to reproduction, screening, prevention and clinical management.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/04/2024 13:43:08 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3960 label Biography information for Henry Smith

1123848

	registered interest
	date	30/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Haematological Cancer: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what his timetable is for whole genome sequencing to be made available to patients with blood cancer; and what assessment he has made of the potential benefits of that sequencing for those patients' care.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	249261
	answer	answer is ministerial correction date of answer 09/05/2019 answer text <p>Up to 50% of cancer patients enrolled in the 100,000 genomes project, including patients with blood cancer, have seen a change in their treatment since receiving their result. This could be eligibility for a new trial, or prescription of a new medicine.</p><p>The National Genomic Test Directory outlines the range of genomic tests – from whole genomic sequencing to tests for single genes and molecular markers – that are available as part of the National Health Service clinical service.</p><p>From summer 2019, whole genome sequencing will be implemented as part of routine clinical care and be available to:</p><p>- Seriously ill children with a suspected genetic disorder, including those with cancer;</p><p>- People with one of 21 rare and inherited conditions; and</p><p>- People with specific types of cancer for which there is likely to be the greatest patient benefit from using whole genome sequencing – children with cancer, sarcoma and acute myeloid leukaemia.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 09/05/2019 14:31:31 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	3960 label Biography information for Henry Smith

1134871

	registered interest
	date	26/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Genomics
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans his Department has to provide training for NHS staff on whole genome sequencing.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	269709
	answer	answer is ministerial correction date of answer 05/07/2019 answer text <p>As part of the NHS Long Term Plan, the National Health Service has committed to sequencing 500,000 whole genomes by 2023/24.</p><p>To deliver this, NHS England is working closely with the NHS Genomic Laboratory Hubs to monitor the workforce plans that are being put in place to support the delivery of the whole genome sequencing (WGS) service. This will continue after the service has launched as part of ongoing monitoring.</p><p>Health Education England established the Genomics Education Programme to support NHS staff to build the knowledge, skills and experience to deliver a WGS service. This programme is being embedded into organisations to enable long term sustainability of the multi-disciplinary, clinical workforce.</p><p><strong> </strong></p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 269710 question first answered 05/07/2019 11:49:13 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	3960 label Biography information for Henry Smith